Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Institutional Variability in Testing for Actionable Genetic Alterations in Patients with Stage IIIB/C or IV NSCLC: Real-World Data from the Prospective, Multicenter CRISP Registry (AIO-TRK-0315)

F. Althoff, H-D. Hummel, K. Kokowski, C. Elender, C. Grah, M. Jaenicke, A. Fleitz, S. Zacharias, A. Groth, P. Ludwig, A. Nusch, M. Reiser, H. Pelz, J.H. Wiegand, F. Griesinger, M. Thomas, W.E.E. Eberhardt, M. Sebastian, ESMO 2025.

Annals of Oncology, Volume 36, Supplement 2, 2025, Pages S1068-S1069, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2025.08.2635

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2025
Combined chemo-immunotherapy versus monoimmunotherapy in advanced high PD-L1 positive NSCLC. Real-world data analyzed with propensity scores technique from the German prospective multicentre registry study (CRISP) (AIO-TRK-0315)

Metzenmacher, M. et al.

Annals of Oncology, Volume 36, Supplement 2, 2025, Page S1092, ISSN 0923-7534.

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2025
Real-world treatment and outcome of patients with stage II-III NSCLC in Germany from 2018-24 (Prospective German Registry CRISP, AIO-TRK-0315)

W.E.E. Eberhardt, B. Passlick, A. Groeschel, D.C.C. Christoph, C. Grah, P. Hoffknecht, P. Ludwig, A. Groth, C. Lennartz, M. Jaenicke, L. Spring, B. Seese, M. Sebastian, F. Griesinger, M. Stuschke, M. Thomas.

Annals of Oncology, Volume 36, Supplement 2, S1060

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2025
Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma – effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study – BERING CRC.

S Stintzing, H Müller-Huesmann, E von der Heyde, I Virchow, R Greil, J Kisro, P Stübs, D Bürkle, A Distelrath, J Wierecky, A Wein, A Gerger, D Arnold, R Fritsch, S Hegewisch-Becker, A Vogel, A Dorothea Wagner, T Winder, D Koeberle, G Prager.

Annals of Oncology, Volume 36, Supplement 1, 2025, Page S25, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2025.05.052

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
BeringCRC
2025
Real-World Incidence of Bleeding Events in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib +/- Obinutuzumab and Requiring Direct Oral Anticoagulation.

K Fenchel, E von der Heyde, M Zaiss, T Illmer, M Schulze, S Jäger, S Schroeder, Daniel Kummer, Patrick Marschner.

Blood (2025) 146 (Supplement 1): 2724. https://doi.org/10.1182/blood-2025-2724

Abstract

Indikation: Lymphatic Neoplasia, Lymphatische Neoplasien / Veranstaltung: ASH / Journal: Blood
CICERO
2025
Prevalence of Claudin 18.2 Expression in Patient Subgroups and Co-expression of Claudin 18.2 with the KRAS G12D Mutation in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma in Germany.

Peter J. Wild, Marco Gross-Langenhoff, Clare McCabe, Julia Bein, Anna Hof, Martin Glasstetter, Georgia Gourgioti, Lawrence Chang, Anouk van Oosten, Holly Dasghaib, Martina Jänicke, Karin Potthoff

Oncol Res Treat 2025;48 (suppl 2):195

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2025
Neoadjuvant nivolumab plus platinum-based chemotherapy in patients with non-metastatic resectable NSCLC: Interim data from the non-interventional study NENI.

Eichhorn, M; Reiser, M; Meyer zum Büschenfelde, C; Faehling, M; Hammerschmidt, S; von der Heyde, E; Hoffknecht, P; Möller, M; Meyn, P; Kokowski, K; Metzenmacher, M; Brueckl, W; Buettner, R; Griesinger, F; Bluhmki, T; Dauber, K; Waldenberger, D; Hillejan, L.

Zentralblatt für Chirurgie 2025; 150(S01): 88 – 89. DOI: 10.1055/s-0045-1809760

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGT / Journal: Zentralblatt für Chirurgie
NENI
2025
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

Goebell PJ, Bögemann M, Nusch A, Grünwald V, Müller L, von der Heyde E, Martens UM, Lennartz C, Koska M, Potthoff K, Kaiser-Osterhues A, Grüllich C, Staehler M, Jänicke M, Marschner D; CARAT Registry Group.

Int J Cancer. 2025 Oct 29. doi: 10.1002/ijc.70211. Epub ahead of print.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: International Journal of Cancer
CARAT
2025
Prospective validation of the metastatic colorectal cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, Schuch A, Serrer L, de Buhr RK, Siebenbach HU, Göhler T, Schröder J, Semsek D, Köhler A, Stübs P, Marschner N.

Int J Cancer. 2025; 1-12. doi:10.1002/ijc.70139

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: International Journal of Cancer
VALIDATE
2025
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer.

Potthoff K, Marschner N, Müller L, Sahm S, Lerchenmüller C, Depenbusch R, Boller E, Niemeier B, Zirrgiebel U, Tesch H.

J Gastrointest Cancer. 2025 Jun 27;56(1):141. doi: 10.1007/s12029-025-01260-6.

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Gastrointestinal Cancer
ERBIMOX
2025